TileDB
TileDB is a multimodal database platform founded in 2017 by Stavros Papadopoulos, who spent three years at Intel's Science and Technology Center for Big Data at MIT CSAIL before starting the company.
Profile
A database platform for managing complex, multimodal scientific data—genomics, imaging, clinical records—alongside analytics and AI workloads in a single system.
TileDB is a multimodal database platform founded in 2017 by Stavros Papadopoulos, who spent three years at Intel's Science and Technology Center for Big Data at MIT CSAIL before starting the company. The Cambridge-based startup has raised $54.3 million across three funding rounds, with a Series B of $34 million in September 2023 led by AlleyCorp (founded by MongoDB co-creator Kevin Ryan). The company now operates with approximately 72 employees across four continents.
The core product is a database engine built on multi-dimensional array technology designed to handle complex, heterogeneous data—genomics sequences, satellite imagery, medical imaging, clinical records, and single-cell datasets—in ways that traditional SQL databases struggle to manage. TileDB Carrara, the company's latest platform release (January 2025), adds collaborative workspaces, unified data catalogs, and native support for Jupyter Notebooks and multiple programming languages. The platform has achieved broad integration into the cloud ecosystem, becoming available through AWS Marketplace (January 2025) and as a Snowflake Connected App (December 2025).
TileDB's market focus is healthcare and life sciences. The company claims trusted relationships with half of the top ten pharmaceutical companies globally, including Johnson & Johnson, Takeda, and Amgen, as well as biotech firms like Cellarity. In July 2025, Gartner recognized TileDB in two Hype Cycle reports covering Trusted Research Environments and Single-Cell Multiomics Systems. Strategic partnerships announced in 2025 include integrations with Databricks (July) for AI-driven drug discovery and a multi-party collaboration with Kepler AI and Tahoe Therapeutics (September) on single-cell data analysis platforms.
Who buys this
- Pharmaceutical and biotech R&D teams managing genomics, proteomics, and clinical data at scale
- Healthcare organizations consolidating electronic medical records, imaging, and genomic data for precision medicine
- Life sciences research institutions building FAIR-compliant data platforms for collaborative discovery
- Financial services and oil & gas firms managing high-dimensional sensor and geospatial data
- Trusted research environments requiring secure multiparty data sharing and governance
Publicly disclosed clients
- Johnson & Johnson
- Quest Diagnostics
- Amgen
- Takeda
- Lockheed Martin
- Cellarity
- Rady Children's Institute
Strengths and what to watch
Strengths
- Array-native architecture handles complex, unstructured scientific data (genomics, imaging, spatiotemporal) that row/column databases treat as opaque blobs
- Integrated ecosystem across AWS, Snowflake, Databricks, and custom notebooks eliminates costly data replication and ETL pipelines in life sciences workflows
- Named adoption by half of top-ten pharma and Gartner Hype Cycle recognition signal institutional credibility in regulated healthcare settings
Watch for
- Customer concentration risk: Heavy dependence on pharmaceutical and life sciences segments; downturns in drug discovery funding or regulatory shifts in precision medicine could impact growth
- Competitive pressure from cloud data warehouses (Snowflake, Databricks) adding multimodal capabilities and from specialized genomics tools (Illumina BaseSpace, 10x Genomics)
- Post-Series B runway: No funding announcements since September 2023; 72-person team and AI-rich product roadmap suggest significant burn, profitability timeline unclear
Recent moves
- 10mo ago TileDB Announces Integration with Snowflake to Launch TileDB Carrara as Snowflake Connected App
- 1y ago TileDB, Kepler AI, and Tahoe Therapeutics Partner to Transform Single-Cell Data Analysis with AI-Powered Platform
- 1y ago TileDB Recognized in Two 2025 Gartner Hype Cycle Reports for Healthcare and Life Sciences
- 1y ago TileDB Announces Partnership with Databricks to Harness Multimodal Data to Power AI in Healthcare and Life Sciences
Key Information
- Industry
- Multi-Model Databases & Abstraction
- Founded
- 2017
- Headquarters
- Cambridge
Frequently Asked Questions
What is TileDB?
TileDB is a multimodal database platform designed to manage complex scientific data—genomics, imaging, and clinical records—alongside analytics and AI workloads in a single system. Founded in 2017 by Stavros Papadopoulos, it uses array-native architecture to handle heterogeneous data that traditional SQL databases struggle to manage.
What types of scientific data does TileDB manage?
TileDB manages genomics sequences, satellite imagery, medical imaging, clinical records, and single-cell datasets—data types relational databases treat as opaque blobs. Its array-native architecture handles these natively, eliminating costly ETL pipelines and data replication that plague typical life sciences workflows.
Which companies use TileDB?
TileDB is trusted by half the top ten pharmaceutical companies—Johnson & Johnson, Takeda, and Amgen—plus biotech firms like Cellarity and healthcare organizations like Quest Diagnostics and Rady Children's Institute. Users consolidate genomics, imaging, and clinical data for precision medicine and drug discovery.
What cloud platforms does TileDB work with?
TileDB integrates with AWS Marketplace, Snowflake as a Connected App, and Databricks. It supports Jupyter Notebooks and multiple programming languages, enabling teams to work in their preferred tools without costly data replication or ETL. January 2025 added AWS availability; December 2025 brought Snowflake integration.
How much funding has TileDB raised?
TileDB has raised $54.3 million across three funding rounds, with a Series B of $34 million in September 2023 led by AlleyCorp, co-founded by MongoDB creator Kevin Ryan. Additional investors include Nexus Venture Partners and Intel Capital. The Cambridge-based startup employs approximately 72 people across four continents.
Who are TileDB's main competitors?
Snowflake and Databricks compete by adding multimodal capabilities; specialized genomics platforms like Illumina BaseSpace and 10x Genomics serve niche segments. TileDB's advantages include array-native architecture, integrated cloud ecosystem spanning AWS, Snowflake, and Databricks, and adoption by half the top-ten pharmaceutical companies.
How TileDB compares
Direct head-to-head against 3 competitors. Picked by 7wData.
TileDB
- Positioning
- A database platform for managing complex, multimodal scientific data—genomics, imaging, clinical records—alongside analytics and AI workloads in a single system.
- Customer segments
- Pharmaceutical and biotech R&D teams managing genomics, proteomics, and clinical data at scale
- Strengths
- Array-native architecture handles complex, unstructured scientific data (genomics, imaging, spatiotemporal) that row/column databases treat as opaque blobs
- Watch for
- Customer concentration risk: Heavy dependence on pharmaceutical and life sciences segments; downturns in drug discovery funding or regulatory shifts in precision medicine could impact growth
- Recent moves
- TileDB Announces Integration with Snowflake to Launch TileDB Carrara as Snowflake Connected App
DNAnexus
- Positioning
- Cloud platform for governed storage, analysis, and workflow orchestration of genomic and multimodal biomedical data in regulated environments.
- Customer segments
- Large pharma R&D, national biobanks, clinical diagnostics labs, hospital systems, and CROs needing compliant multiomics infrastructure.
- Strengths
- Operates UK Biobank Research Analysis Platform, demonstrating proven large-scale population genomics infrastructure under real regulatory and data-governance constraints.
- Watch for
- Bioinformatics team hollowed out post-cost cuts and science team attrition noted on Glassdoor, signaling internal delivery risk.
- Recent moves
- May 2026: launched Omics Data Catalog, Analysis Accelerators, and integrations with Oracle Health and AlidaBio at annual conference.
Velsera
- Positioning
- PE-assembled precision medicine platform combining bioinformatics compute, clinical NGS reporting, and variant interpretation under one stack.
- Customer segments
- Large pharma R&D teams, clinical NGS diagnostic labs, government and academic genomics programs including NIH.
- Strengths
- 950-plus validated bioinformatics workflows and 18,000-plus researchers on a single cloud-native CWL/WDL/Nextflow compute layer.
- Watch for
- Post-merger leadership instability: RepVue scores 2.3/5 on culture and strategic direction following Summa Equity consolidation of three acquisitions.
- Recent moves
- April 2025: launched Global Data Network with 175 million-plus patient records across 50-plus data partners for drug discovery.
Benchling
- Positioning
- Cloud R&D platform serving as system of record for biology data across drug discovery and process development.
- Customer segments
- Biotech and pharma R&D teams, enterprise-skewed, from discovery startups to large biopharma like Merck and Sanofi.
- Strengths
- End-to-end antibody discovery workflow combining ELN, biologics registry, and sequence analysis in one platform.
- Watch for
- File management and navigation consistently rated poor on G2, creating friction in data and sample tracking workflows.
- Recent moves
- August 2025: acquired ReSync Bio to strengthen compute and experiment management across the design-make-test-analyze cycle.
Sources
- www.tiledb.com — TileDB's mission, leadership team (Stavros Papadopoulos as Founder/CEO), board of directors, and core values
- www.tiledb.com — Series B funding of $34M in September 2023 led by AlleyCorp, board additions, investors including Two Bear Capital, Nexus Venture Partners, Intel Capital, Lockheed Martin Ventures, strategic direction
- tracxn.com — Total funding of $54.3M across 7 rounds, investor list, and Series B details
- www.prnewswire.com — AWS Marketplace availability announced January 23, 2025, CEO quote from Stavros Papadopoulos, use cases and customer example (Cellarity)
- www.prnewswire.com — Gartner Hype Cycle recognition in July 2025 for Trusted Research Environments and Single-Cell Multiomics Systems
- www.prnewswire.com — July 2025 Databricks partnership, CEO quote, target market (healthcare and life sciences), problem statement on data silos
- www.tiledb.com — TileDB Carrara platform features (Organize, Structure, Collaborate, Analyze), pricing model, target applications
- leadiq.com — Employee count of approximately 72 as of July 2025, with operations across 4 continents